AbbVie Shares Drop Despite Raising Annual Profit Outlook on Skyrizi Strength
Financial Modeling Prep· 2025-10-31 19:24
Core Insights - AbbVie Inc. raised its full-year profit forecast due to strong demand for its psoriasis treatment Skyrizi, leading to third-quarter sales that exceeded expectations, although shares fell over 4% in intra-day trading [1] Financial Performance - For the quarter ending in September, AbbVie reported a net revenue increase of 9.1% year-over-year, reaching $15.78 billion, driven by strong sales of Skyrizi and Rinvoq [2] - Adjusted earnings per share for the quarter were $1.86, a decrease from $4.86 a year earlier, but above Bloomberg's consensus estimate of $1.77 [2] Product Performance - The growth in immunology products helped mitigate the decline in Humira, which has faced significant competition from lower-cost biosimilars since 2023 [3] - Rinvoq generated $5.97 billion in revenue in 2024, representing approximately half of AbbVie's total sales, with expectations that Rinvoq and Skyrizi will together contribute about $31 billion in revenue by 2027 [3]
Sealed Air Set to Report Q3 Earnings: What's in Store for the Stock?
ZACKS· 2025-10-31 19:22
Key Takeaways Sealed Air will report 3Q25 results on Nov. 4, before market open.Consensus calls for $1.31B in sales and EPS of $0.68, suggesting y/y declines.Cost savings from the Reinvent SEE Strategy may have boosted operating margins.Sealed Air Corporation ((SEE) is scheduled to report third-quarter 2025 results on Nov. 4, before the opening bell.The Zacks Consensus Estimate for SEE’s third-quarter net sales is pegged at $1.31 billion, indicating a 2.4% decline from the year-ago reported figure.The conse ...
Strategy Q3 Earnings Beat Estimates, Revenues Increase Y/Y
ZACKS· 2025-10-31 19:22
Key Takeaways Strategy posted Q3 EPS of $8.42 versus a $1.56 loss last year, beating expectations.Revenues rose 11% to $128.7 million, led by a 63% jump in product licenses and subscriptions.Operating income hit $3.9B, boosted by a $3.89B unrealized gain on digital assets. Strategy (MSTR) reported third-quarter 2025 earnings of $8.42 per share against the year-ago quarter loss of $1.56 per share. The Zacks Consensus Estimate was pegged at a loss of 11 cents per share. Revenues of $128.7 million beat the Zac ...
10-year Treasury yield holds above 4%
Youtube· 2025-10-31 19:22
Rick Santelli joining us now from Chicago with the bond report. Rick, I went on like a it was like a 10-second mini rant yesterday, but the the gist was basically this. The Federal Reserve can say and do what it wants. The bond market is the boss and the bond market is going to do what it wants and it wanted and wants clearly to take interest rates if not higher, not lower.Yeah, it's a very interesting dynamic, especially for those that are in the current administration or those that are looking towards hou ...
Coinbase in late-stage talks to buy stablecoin firm BVNK for $2B - report (COIN:NASDAQ)
Seeking Alpha· 2025-10-31 19:22
Coinbase Global (COIN) is nearing a roughly $2B acquisition of stablecoin infrastructure startup BVNK, in a deal that's expected to close later this year or early next, according to a Friday media report. Terms of the deal have not been ...
Silgan Beats Q3 Earnings Estimates, Trims '25 Outlook on Low Volumes
ZACKS· 2025-10-31 19:22
Key Takeaways Silgan posted Q3 adjusted EPS of $1.22, beating estimates and rising 1% y/y.Revenues climbed 15% to $2.01B, led by gains in the Dispensing and Metal Containers segments.The company cut the 2025 EPS guidance to $3.66-$3.76, citing softer expected volumes ahead.Silgan Holdings Inc. ((SLGN) reported adjusted earnings of $1.22 per share in third-quarter 2025, beating the Zacks Consensus Estimate of $1.21. The bottom line increased 1% year over year and was within the company’s guidance of $1.18-$1 ...
Amazon Q3 Earnings Beat Estimates, AWS Growth Pushes Stock Higher
ZACKS· 2025-10-31 19:22
Key Takeaways Amazon Q3 earnings beat estimates by 23%, with shares jumping 13% on strong results.AWS revenues grew 20% year over year to $33 billion, though lagging Google and Microsoft growth.Net income surged 38% to $21.2 billion, boosted by $9.5 billion in pre-tax Anthropic gains.Amazon.com (AMZN) shares jumped more than 13% in extended trading on Thursday after the company delivered third-quarter 2025 earnings of $1.95 per share, which increased 36.4% from the year-ago quarter and beat the Zacks Consen ...
Bloom Energy vs. Plug Power: Which Fuel-Cell Stock Should You Buy Now?
ZACKS· 2025-10-31 19:22
Key Takeaways Bloom Energy and Plug Power both show strong earnings growth prospects for 2025 and 2026.BE's ROIC of 4.62% far outpaces PLUG's -57.91%, highlighting more efficient capital use.BE's TIE of 1.3 versus PLUG's -36.1 shows stronger debt servicing capacity and stability.Fuel cell technology is becoming increasingly vital as the global shift toward clean and sustainable energy gains momentum. By generating electricity from hydrogen or other fuels through an electrochemical reaction, fuel cells deliv ...
CNX Resources Tops Q3 Earnings Estimates, Ups '25 Production Volume
ZACKS· 2025-10-31 19:21
Key Takeaways CNX Resources' Q3 earnings of 49 cents beat estimates and rose 19.5% from last year.Revenues climbed 19.5% to $423 million on higher production volumes and cost control.CNX repurchased 6.1M shares and raised 2025 production guidance to 620-625 Bcfe.CNX Resources Corporation (CNX) reported third-quarter 2025 operating earnings of 49 cents per share, which beat the Zacks Consensus Estimate of 37 cents by 32.4%. The bottom line also increased 19.5% from 41 cents in the year-ago quarter.CNX’s Reve ...
AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues
ZACKS· 2025-10-31 19:21
Key Takeaways Agios reported a Q3 loss of $1.78 per share, beating expectations of a loss of $1.93.AGIO's total revenues climbed 44% year over year to $12.9 million, fueled by Pyrukynd sales.The FDA decision on Pyrukynd's thalassemia indication is due on Dec. 7, as the EMA gives a positive opinion.Agios Pharmaceuticals (AGIO) incurred a loss of $1.78 per share in the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.93. In the year-ago quarter, the company had reported earnin ...